An interventional study of Morphine pharmacokinetic evaluation in Pediatric Sleep Apnea, Obesity and Morphine Metabolism, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 5 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-09.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment
Adenotonsillectomy (AT) is one of the most common pediatric surgeries performed, and is estimated to comprise 530,000 procedures in children under 15 years of age. Historically, the leading cause for these procedures was recurrent infections; however, more recently surgical indications include sleep disordered breathing and obstructive sleep apnea (OSAS). Pre-operative polysomnography (PSG) is recommended for all children with suspected OSAS prior to undergoing AT, although it is unclear whether sleep disordered breathing characteristics predict post-operative outcomes or complications.
Obesity has become an epidemic in the pediatric population. More recently, an increased population of obese children are presenting for AT with upper airway obstruction with or without tonsillar hypertrophy, which is similar to the adult etiology of OSAS. Obesity is a multisystem disease, causing fatty liver and cardiac disease, defects in glucose metabolism, insulin resistance, leptin resistance, and creates a state of chronic inflammation. Markers for inflammation, including tumor necrosis factor (TNF)-α, C-reactive protein (CRP), leptin, interleukin (IL)-6 and IL-10, are abnormal in obese patients and have also been linked to more severe OSAS disease in children even after controlling for BMI.
In pediatrics, medication dosing is based on an actual body-weight calculation, however, recent reports suggest that this dosing method is over-dosing patients with obesity. Therefore, increased respiratory complications after surgery may be related to inappropriate intra-operative opioid dosing.
Specific Aim 1 (SA1): To compare morphine pharmacokinetics in normal children \<=12 years of age, non-obese children with severe OSAS, and obese children with severe OSAS. The investigators hypothesize that obesity independently enhances morphine pharmacokinetics.
Specific Aim 2 (SA2): To determine whether biomarkers related to obesity, chronic inflammation, and OSAS predict changes to morphine pharmacokinetics. The investigators hypothesize that inflammatory and obesity-related biomarkers are elevated in overweight children with OSAS, more so in obese children with OSA, compared to lean children with OSAS. In addition, the investigators hypothesizes that leptin independently is linked to altered morphine pharmacokinetics.
1,422 studies on the registry are indexed under Apnea; 159 are open to participants now.
This study's enrollment of 43 is below the median of 50 across 965 interventional studies indexed under Apnea.
Browse Apnea studies →Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.
Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
OSAS group:
Obese:
Exclusion Criteria:
Evaluating morphine pharmacokinetics (PK) in 3 groups: normal controls, children with severe OSAS, and obese children with OSAS. Morphine is dosed on ideal body weight in obese children, as recommended by manufacturer. Biomarkers were taken from patients to evaluate their relation to changes in morphine PK.
Other: Morphine pharmacokinetic evaluation
Each group received morphine and blood drawn to evaluate morphine PK
Plasma Morphine Area Under the Curve (AUC)
To determine changes in morphine AUC due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Maximum Plasma Morphine Concentration (Cmax)
To determine changes in morphine Cmax due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Time to Maximum Plasma Morphine Concentration (Tmax)
To determine changes in morphine Tmax due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Half Life of Plasma Morphine Concentration (T1/2)
To determine changes in morphine T1/2 due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Plasma Morphine Clearance (Cl)
To determine changes in morphine Cl due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Plasma Morphine Volume of Distribution (Vd)
To determine changes in morphine Vd due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Plasma Morphine 3-glucuronide (M3G) Maximum Plasma Concentration (Cmax)
To determine changes in M3G Cmax due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Time to Maximum Morphine 3-glucuronide (M3G) Concentration (Tmax)
To determine changes in M3G Tmax due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Morphine 3-glucuronide (M3G) to Morphine ratio
To determine changes in metabolism of morphine due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Morphine 3-glucuronide (M3G) to Morphine 6-glucuronide (M6G) ratio
To determine changes in metabolism of morphine due to obesity and OSAS
Time frame: Through study completion, up to 24 hours after study initiation
Biomarker concentrations
To determine whether inflammatory biomarkers correlate to the severity of sleep apnea. Biomarkers that will be studied include IL 1,6,10, CRP, TNF-alpha, leptin, and insulin.
Time frame: Through study completion, up to 24 hours after study initiation
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins University